Physician profile
Dawn Tree
NPI 1063836237
$3,919.30
in general payments reported to CMS, 2019-2025
22 companies · $15.78 in 2025
The $15.78 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $1,413 · 2023: $1,145 · 2024: $140 · 2025: $15.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.23 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $482.30 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $435.21 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $406.37 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Avanir Pharmaceuticals, INC. | $363.64 | 2021-2022 | |
| Lundbeck LLC | $362.54 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $198.17 | 2022-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $191.68 | 2021-2022 | |
| Axsome Therapeutics, INC. | $170.61 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $142.32 | 2022-2023 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $114.81 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $82.61 | 2022-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $82.58 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $79.80 | 2022-2024 | Loreev Xr |
| Adlon Therapeutics L.P. | $68.16 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $55.48 | 2022 | |
| Corium, LLC | $53.23 | 2022-2023 | Azstarys |
| Galderma Laboratories, L.P. | $19.71 | 2023 | |
| Arbor Pharmaceuticals, INC. | $19.44 | 2021 | |
| Neos Therapeutics, Lp | $18.49 | 2023 | Adzenys Xr-Odt |
| Merz North America, INC. | $17.41 | 2022 | |
| Alfasigma USA, INC. | $14.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Tree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.